Costa Rica or Mexico for Medical Device Manufacturing? A 2026 Product-Fit Comparison

By Ricardo Rascon, Director of Marketing at Tetakawi · Updated July 28, 2026

Comparisons of Costa Rica medical device manufacturing against Mexico usually blur three different decisions: placing a new program, adding second-source capacity, and transferring an existing validated line. They deserve separate answers, because a validated Costa Rican operation carries transfer, revalidation, and regulatory costs that can outweigh a tariff or labor difference. This analysis is written for the first two, and for transfers already under consideration; for many portfolios the realistic outcome is Costa Rica and Mexico serving different programs side by side. Every material figure below is labeled by evidence type.

Why Costa Rica Wins

According to CINDE, citing national export data, Costa Rica’s medical device exports reached nearly US $11 billion in 2025 and represented approximately 48% of the country’s goods exports, its largest export category. CINDE reports more than 90 MedTech multinational companies operating there and ranks the country the world’s tenth-largest device exporter; the sector directly employed more than 58,000 people at year-end 2024, per PROCOMER data published by Coyol Free Zone. A company choosing Costa Rica gets a mature regulatory ecosystem, deep sterilization and supplier relationships, a bilingual workforce, and two decades of institutional experience serving the FDA-regulated market. Programs built around that ecosystem have a strong case for staying.

Constraints to Model at Scale

The same success has produced constraints that belong in any five-year model. Concentration: according to Coyol Free Zone’s own reporting, that single park accounts for approximately 55% of the country’s medtech exports and roughly 42% of its direct employment (park-reported figures; underlying periods run through 2024), so new programs add demand within an already dense labor and supplier market. Industry reporting through 2025 and 2026 describes a competitive market for STEM and bilingual talent, and the economy-wide context agrees: in a PwC survey of 437 Costa Rican employers across sectors, 86% reported salary adjustments between November 2025 and April 2026, and among employees who departed, 26% left within their first three months. That is economy-wide context, not a medtech turnover statistic, but it is the market every medtech recruiter hires in.

Currency should be modeled symmetrically. On point-to-point reference rates over a comparable mid-2022-to-late-July-2026 period, the colón moved from roughly ¢696 per dollar to approximately ¢454 (Banco Central de Costa Rica reference rate): about 35% fewer colones per dollar, meaning that, holding the local-currency expense constant, a fixed colón-denominated cost now translates into roughly 53% more dollars. The Mexican peso moved from approximately MXN 20.13 to MXN 17.43 per dollar (Banco de México FIX rate), which, holding the local-currency expense constant, is an increase of approximately 15.5% in the dollar translation of a fixed peso expense. These are point-to-point observations, not forecasts, and they measure currency translation, not local wage inflation; stress-test both, separating local-currency costs like payroll from dollar-linked costs like rent, imported materials, and equipment. The question is exposure by cost bucket, not which currency appreciated more.

The Tariff Framework

As of July 24, 2026, the Section 301 action finalized by the U.S. Trade Representative generally places Costa Rica-origin goods in a 12.5% additional-duty tier, subject to the action’s Annex I and Annex II exclusions and its in-transit exception. Mexico sits in the 10% tier, but the notice exempts products of Mexico entered free of duty under USMCA. Costa Rican goods also paid additional duties under earlier economy-wide actions from April 2025 through July 2026 while USMCA duty-free Mexican goods were exempted from each; that history is a pattern in how these actions have been drafted, not a guarantee of future policy. Separately, in an October 2025 filing in the Commerce Department’s open Section 232 investigation covering medical equipment and supplies, Costa Rica requested tariff-free treatment for its device exports; that proceeding is distinct from the Section 301 duty.

Five qualifications belong next to that table. A Mexican manufacturing location does not automatically establish USMCA qualification; treatment depends on the finished product’s HTS classification, product-specific rule of origin, bill-of-materials origin, certification, and exclusions. The additional duty is assessed on the applicable entered customs value, not on company revenue. Ordinary duties, AD/CVD, and Section 232 measures apply separately, and the open medical-supplies Section 232 investigation could reach both countries; precedent in the parallel pharmaceutical action suggests a USMCA exemption there is a possibility, not a guarantee. Rates can change with negotiations, and customs counsel should validate the result for the actual product before any decision relies on it.

Free Zones, Translated

Executives who know Costa Rica think in free-zone terms, and four operating structures are on the menu: an own entity inside Costa Rica’s Free Trade Zone Regime, a Costa Rican contract manufacturer, an own Mexican entity operating under IMMEX, and a Mexican shelter-serviced operation. Costa Rica’s Free Trade Zone Regime principally provides qualifying tax and customs treatment; many participating manufacturers locate in private free-zone parks that separately provide infrastructure and operating services, and a company using an established contract manufacturer may not need a local operating organization at all. Free-zone status by itself does not determine U.S. import treatment, which depends on origin qualification, HTS classification, and applicable product-specific trade measures.

Mexico’s IMMEX program permits qualifying temporary imports for export production; duty and VAT treatment depends on the merchandise, origin, program requirements, and applicable certification or guarantee structure. A shelter adds a managed operating platform under which the foreign manufacturer conducts the sheltered activity without establishing its own Mexican operating subsidiary: the operator administers specified employment, payroll, customs, and administrative obligations by contract, while the manufacturer retains its product-quality, FDA, design, and intellectual-property responsibilities. The relevant question is whether you want to build and manage your own local organization or use a managed operating structure. At Tetakawi’s Mazatlán Manufacturing Campus, that managed structure operates inside a single 100-acre park.

The Wage Question

The two most quotable wage numbers are different evidence types and are not directly comparable, so read them as brackets, not a verdict. For Costa Rica, the public anchor is statutory: the 2026 wage decree sets the monthly minimum for an unskilled worker at ¢373,092. Tetakawi’s illustrative model of the employer cost at that legal floor, adding social-security contributions, the mandatory Christmas bonus, and paid-leave accruals, converted at ¢454 per dollar over 208 paid hours, works out to approximately $5.54 per hour before voluntary benefits. That is a modeled legal-floor scenario, not a published medtech market wage; within a national sector containing more than 90 MedTech multinationals, prevailing compensation for trained roles is likely to exceed the statutory floor, particularly within the principal Central Valley clusters. For Mexico, the number is internal: Tetakawi’s current Mazatlán operating model, converted at MXN 17.42 per dollar, places fully fringed entry-operator employer costs at approximately $4.75 to $5.80 per hour, and Tetakawi’s 2026 benchmarking across more than 60 manufacturers places the comparable northern-border cost at $7.50 to $8.50; each is a Tetakawi internal 2026 operating benchmark, not a published national market average. These figures should not be subtracted from one another; they use different methodologies and are included only to establish plausible cost brackets.

A like-for-like comparison uses the same role and shift, statutory burden, benefits, paid nonproductive hours, absenteeism, turnover, training cost, ramp productivity, and a common currency date; it can only be built program by program, and it is worth building before believing any single per-hour figure, including ours. Costa Rica remains entirely cost-viable for medical manufacturing. The five-year model should weigh both cost level and variability on each side: Costa Rica’s statutory indexation compounding with the currency movement above, and Mexico’s phased statutory reduction of the workweek from 48 to 40 hours between 2027 and 2030 under the March 3, 2026 constitutional decree and its May 1, 2026 implementing labor-law decree, which provide that the reduction may not reduce wages, salaries, or benefits; its cost effect depends on shift design, headcount, productivity, and overtime.

What a Transfer Changes

Medical device site selection is not a real-estate decision with a wage attached. Depending on the product and regulatory pathway, moving or adding a line can involve manufacturing-site change analysis; a 510(k), PMA supplement, notification, or customer approval where applicable; equipment installation and qualification; process, packaging, and sterilization validation; cleanroom construction and qualification; supplier requalification; calibration, metrology, and laboratory support; training records; an inventory bridge; and ramp yield costs. None of that is uniform; the effect is product- and pathway-specific and belongs with the manufacturer’s quality and regulatory teams. FDA’s QMSR, effective February 2, 2026, incorporates ISO 13485’s personnel-competence requirements, which is why trained-operator stability matters to a quality system, an argument developed in our site-selection framework and retention analysis. Lower turnover can support training continuity, personnel competence, and process discipline; it does not by itself establish QMSR compliance or validated manufacturing readiness.

Where Profiles Fit

The choice is rarely country versus country; it is profile versus location, including where in Mexico. Baja California is Mexico’s most established medical device manufacturing cluster, with Ciudad Juárez the border’s other leading hub. No location on this table is a universal winner.

The Mazatlán Case

Any serious screen of the third row starts with both halves of lower industry concentration. Fewer regulated manufacturers may reduce direct competition for labor relative to established medtech clusters. The trade-off is likely to be fewer immediately experienced device operators, engineers, validation specialists, quality leaders, suppliers, and laboratories on the ground today. The second half does not disqualify the location; it defines the training and investment plan, and the screen should price it.

Per Tetakawi’s regional workforce analysis (internal estimate, 2025, covering an approximately 30-mile commuting radius): more than 500,000 people, median age 31, more than 29,000 students across 21 universities and technical institutions, and approximately 5,250 graduates annually, 35% in technical fields. Tetakawi also maintains a working relationship with Conalep, Mexico’s national technical education system, for technical training. The physical starting point: move-in-ready Class A space is available now, with climate control installed across production floor, offices, and services and contracted utility capacity, detailed in our industrial space primer. Climate control is a starting condition for controlled-environment assembly, not a classified cleanroom; cleanroom design, construction, and qualification are part of the program plan. On freight, Tetakawi estimates one to three linehaul days from Mazatlán to U.S. border crossings, excluding customs and final delivery; the decision-grade comparison is door to door against your actual destinations.

Honesty about fit belongs here too. Mazatlán is not a substitute for Costa Rica’s complete medical device ecosystem, and it may not be the strongest fit when a program depends on nearby sterilization, a mature contract-manufacturing network, multiple validated suppliers close by, highly specialized medtech engineering talent, or a product that cannot qualify under USMCA. It merits screening for new or second-source programs matching the profile above. As for any site outside an established medtech cluster, due diligence should inventory sterilization access, cleanroom design and certification resources, calibration and metrology, testing laboratories, packaging-validation support, tooling and maintenance, regulated waste handling, quality and regulatory leadership, supplier depth, logistics, and power quality and clean utilities.

How to Decide

Screen first, then model. The screen asks whether the program is supplier-light, whether the product can qualify under USMCA, whether trained-operator stability drives the quality system, and where the volume ships. The model then runs five years of total cost and risk, not wages and tariffs alone: HTS and origin qualification, annual customs value, supplier geography, labor by role and shift, turnover and training, currency exposure by cost bucket, facility and utilities, freight and inventory carrying cost, regulatory transfer cost, validation, tax and customs structure, staffing, business continuity, and time to validated commercial production. On launch speed, the accurate claim is narrower than a production date: initial occupancy and operational setup may begin in as little as 30 days for suitable projects, as detailed in the FAQ below. The numbers here are current as of July 28, 2026, and trade policy is moving quarterly.

Frequently Asked Questions

Why do medical device companies manufacture in Costa Rica?

Two decades of cluster development made Costa Rica medical device manufacturing a global benchmark: per CINDE, citing national export data, devices reached nearly $11 billion in 2025 exports, approximately 48% of the country’s goods exports, supported by free-zone incentives, a bilingual workforce, and more than 90 MedTech multinational companies.

Is Costa Rica or Mexico better for medical device manufacturing?

Neither in general; the answer is profile-specific. Costa Rica is often strongest for programs tied to its established suppliers and contract manufacturers; border Mexico merits screening when supplier density is binding; Mexico’s west coast merits screening for supplier-light, retention-sensitive, U.S.-bound assembly where USMCA treatment materially changes landed cost.

Does Mexico have free trade zones like Costa Rica?

Not as legal equivalents. Costa Rica’s free-zone regime principally grants tax and customs treatment. Mexico’s IMMEX program permits qualifying temporary imports for export production, and its shelter structure adds a managed operating platform: production runs under the shelter’s registration and entity, with specified obligations handled by the operator, while the manufacturer retains its product-quality and regulatory responsibilities.

Do Mexican-made devices avoid the new U.S. tariffs?

Not automatically. The exemption applies to products of Mexico entered free of duty under USMCA; manufacturing in Mexico does not by itself establish that qualification, which depends on HTS classification, the product-specific rule of origin, BOM origin, certification, and exclusions. Mexican products without USMCA duty-free treatment are generally subject to an additional 10% duty, and other measures can apply separately. Customs counsel should confirm treatment for the specific product.

How fast can a medical device line launch in Mexico?

For suitable projects using available space and existing shelter infrastructure, initial occupancy and operational setup may begin in as little as 30 days, because the shelter platform accelerates entity, employment, payroll, customs, and facility setup. A standalone structure generally takes materially longer to establish the entity, registrations, customs platform, workforce, and facility. In either model, product-specific installation, qualification, validation, customer approvals, and regulatory requirements determine the commercial-production date.